🇺🇸 FDA
Patent

US 12240917

Anti-complement C1s antibodies and uses thereof

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 12240917 (Anti-complement C1s antibodies and uses thereof) held by Bioverativ USA Inc. expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Bioverativ USA Inc.
Grant date
Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K49/00